Antiepileptics for aggression and associated impulsivity
Information
- DOI:
- https://doi.org/10.1002/14651858.CD003499.pub3Copy DOI
- Database:
-
- Cochrane Database of Systematic Reviews
- Version published:
-
- 17 February 2010see what's new
- Type:
-
- Intervention
- Stage:
-
- Review
- Cochrane Editorial Group:
-
Cochrane Developmental, Psychosocial and Learning Problems Group
- Copyright:
-
- Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Article metrics
Altmetric:
Cited by:
Authors
Contributions of authors
RN, NH and MF helped prepare the protocol; HJ, MF and NH examined results of searches and independently assessed studies; NH & MF extracted data and assisted in writing the report; HJ assisted in editing the report; RN provided adjudication and assisted in selecting studies and in writing the report.
Sources of support
Internal sources
-
Nottinghamshire Healthcare NHS Trust, UK.
External sources
-
NHS Cochrane Collaboration Programme Grant Scheme, UK.
Declarations of interest
None known.
Acknowledgements
We gratefully acknowledge: David Fearnley's contribution in preparing an earlier version of the protocol; Toby Lasserson (Cochrane Airways Group, UK) for translation of a study in German; Celia Almeida (University of the West of England, UK) for translation of a study in Spanish; Jane Dennis (Cochrane DPLPG, UK) for translation of a study in Swedish; Jo Abbott (Cochrane DPLPG) for running the electronic searches, and Cathy Bennett for advice and helpful comments on an early draft of this review.
Version history
| Published | Title | Stage | Authors | Version |
| 2010 Feb 17 | Antiepileptics for aggression and associated impulsivity | Review | Nick Huband, Michael Ferriter, Rajan Nathan, Hannah Jones | |
| 2008 Oct 08 | Antiepileptics for aggression and associated impulsivity | Protocol | Nick Huband, Michael Ferriter, Rajan Nathan, Hannah Jones | |
| 2002 Jan 21 | Antiepileptics for aggression and impulsiveness | Protocol | David Fearnley, Taj Nathan | |
Differences between protocol and review
The review includes two additional outcomes not specified in the original protocol. These were:
-
number of overall clinical responders (reported by Hellings 2005 in a trial of valproate for outpatient children and adolescents with pervasive developmental disorder);
-
patient‐rated global improvement (reported by Mattes 2008 in a trial of levetiracetam and by Mattes 2005 in a trial of oxcarbazepine, both for outpatients with intermittent explosive disorder).
We chose to include them because none of the prespecified outcomes provided information on global change.
The review omits two analyses specified in the original protocol because of insufficient data. These were:
-
subgroup analysis of effect on primary outcome of participants' age, diagnosis, setting and class of drug.
-
sensitivity analysis to investigate the robustness of findings concerning concealment of allocation, blinding of outcome assessors, and extent of dropouts.
Notes
We note that terms such as 'episodic dyscontrol syndrome' and 'intermittent aggression' are now being used more frequently in the literature. Selection of electronic search terms in any update of this review may wish to take this into account.
